The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The aim of this prospective randomized double-blind study was to compare the efficacy of new
pharmaceutical composition containing botulinum toxin injection in epicardial fat pads for
preventing recurrences of atrial tachyarrhythmia in patients with paroxysmal atrial
fibrillation undergoing coronary artery bypass grafting.
Phase:
Phase 2
Details
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation